ADARx Pharmaceuticals has a total of 34 patents globally, out of which no patents have been granted. Of these 34 patents, more than 91% patents are active. Australia and Canada is where ADARx Pharmaceuticals has filed the maximum number of patents, followed by Brazil. Parallelly, United States of America seems to be the main focused R&D centre and also is the origin country of ADARx Pharmaceuticals.
ADARx Pharmaceuticals was founded in 2019. ADARx Pharmaceuticals is a biotechnology firm. The company creates a patented RNA targeting platform to treat a variety of diseases in the therapeutic domains, such as central nervous system, cardiometabolic, and genetic disorders.
Do read about some of the most popular patents of ADARx Pharmaceuticals which have been covered by us in this article and also you can find ADARx Pharmaceuticals patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over ADARx Pharmaceuticals patent portfolio.
How many patents does ADARx Pharmaceuticals have?
ADARx Pharmaceuticals has a total of 34 patents globally. These patents belong to 11 unique patent families. Out of 34 patents, 31 patents are active.
How Many Patents did ADARx Pharmaceuticals File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | ADARx Pharmaceuticals Applications Filed | ADARx Pharmaceuticals Patents Granted |
| 2023 | 10 | – |
| 2022 | 9 | – |
| 2021 | 15 | – |
How many ADARx Pharmaceuticals patents are Alive/Dead?
Worldwide Patents
How Many Patents did ADARx Pharmaceuticals File in Different Countries?
Countries in which ADARx Pharmaceuticals Filed Patents
| Country | Patent |
| Australia | 3 |
| Canada | 3 |
| Brazil | 2 |
| United States of America | 2 |
| New Zealand | 2 |
| Singapore | 2 |
| Taiwan | 2 |
| Europe | 2 |
| South Africa | 2 |
| Israel | 2 |
| Mexico | 2 |
Where are Research Centers of ADARx Pharmaceuticals Patents Located?
The Research Center for ADARx Pharmaceuticals is the United States of America.
List of ADARx Pharmaceuticals patents
| ADARx Pharmaceuticals Patents | Title |
| US20230272391A1 | Adar Dependent Editing Compositions And Methods Of Use Thereof |
| US20230158059A1 | Prekallikrein-Modulating Compositions And Methods Of Use Thereof |
| EP4225322A1 | N-Acetylgalactosamine(Galnac)-Derived Compounds And Oligonucleotides |
| EP4189088A1 | Adar Dependent Editing Compositions And Methods Of Use Thereof |
| WO2023168296A3 | Cb1 Ligand Conjugated Compounds And Uses Thereof |
| WO2023196342A1 | Α 4Β 1/7 Integrin Ligand Conjugated Compounds And Uses Thereof |
| WO2023192630A2 | Angiotensinogen-Modulating Compositions And Methods Of Use Thereof |
| WO2023154896A3 | Trkb Ligand Conjugated Compounds And Uses Thereof |
| WO2023097291A1 | Complement Factor B-Modulating Compositions And Methods Of Use Thereof |
| WO2023056446A1 | Angiotensinogen-Modulating Compositions And Methods Of Use Thereof |
| WO2023056440A1 | Prekallikrein-Modulating Compositions And Methods Of Use Thereof |
| CA3216732A1 | Rna Silencing Agents And Methods Of Use |
| CA3198406A1 | N-Acetylgalactosamine(Galnac)-Derived Compounds And Oligonucleotides |
| CA3190477A1 | Adar Dependent Editing Compositions And Methods Of Use Thereof |
| AU2022257002A1 | Rna Silencing Agents And Methods Of Use |
| AU2021359017A1 | N-Acetylgalactosamine(Galnac)-Derived Compounds And Oligonucleotides |
| AU2021315812A1 | Adar Dependent Editing Compositions And Methods Of Use Thereof |
| MX2023004170A | Compounds And Oligonucleotides Derived From N-Acetylgalactosamine (Galnac) |
| MX2023001257A | Editing Compositions Dependent On Endogenous Adenosine Deaminase Acting On Ribonucleic Acid And Methods For Use Them. |
| TW202340463A | Complement Factor B-Modulating Compositions And Methods Of Use Thereof |
| BR112023006564A2 | Compounds Derivatives Of N-Acetylgalactosamine (Gainac) And Oligonucleotides |
| TW202322825A | Prekallikrein-Modulating Compositions And Methods Of Use Thereof |
| IL302000A | N-Acetylgalactosamine(Galnac)-Derived Compounds And Oligonucleotides |
| SG11202302717RA | N-Acetylgalactosamine(Galnac)-Derived Compounds And Oligonucleotides |
| ZA202305007A | N-Acetylgalactosamine(Galnac)-Derived Compounds And Oligonucleotides |
| BR112023001641A2 | Adar-Dependent Edition Compositions And Methods Of Using Them |
| IL300241A | Adar Dependent Editing Compositions And Methods Of Use Thereof |
| SG11202300674RA | Adar Dependent Editing Compositions And Methods Of Use Thereof |
| ZA202301603A | Adar Dependent Editing Compositions And Methods Of Use Thereof |
| NZ799007A | N-Acetylgalactosamine(Galnac)-Derived Compounds And Oligonucleotides |
| NZ796915A | Adar Dependent Editing Compositions And Methods Of Use Thereof |
| WO2022221457A1 | Rna Silencing Agents And Methods Of Use |
| WO2022076922A1 | N-Acetylgalactosamine(Galnac)-Derived Compounds And Oligonucleotides |
| WO2022026928A1 | Adar Dependent Editing Compositions And Methods Of Use Thereof |
What are ADARx Pharmaceuticals key innovation segments?
What Technologies are Covered by ADARx Pharmaceuticals?
The chart below distributes patents filed by ADARx Pharmaceuticals